Cagrilintide/semaglutide - Novo Nordisk
Alternative Names: CagriSema; NN-9388; Semaglutide/Cagrilintide - Novo NordiskLatest Information Update: 11 Jun 2026
At a glance
- Originator Novo Nordisk
- Class Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Obesity therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Amylin receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Obesity
- Phase III Type 2 diabetes mellitus
- Phase II Alcoholic liver disorders; Diabetic neuropathies
Most Recent Events
- 11 Jun 2026 Efficacy and adverse events data from a phase III REIMAGINE 3 trial in Type 2 diabetes mellitus released by Novo Nordisk
- 07 Jun 2026 Efficacy and adverse events data from a phase III REIMAGINE 1 trial in Type 2 diabetes mellitus released by Novo Nordisk
- 07 Jun 2026 Efficacy and adverse events data from a phase III REIMAGINE 2 trial in Type 2 diabetes mellitus released by Novo Nordisk